In the world of modern medicine, timely access to innovative treatments can make all the difference for patients battling serious illnesses. A groundbreaking study from Brown University School of Public Health has shed new light on why patients in the United States frequently gain access to new prescription drugs ahead of their counterparts in the European Union, Canada, Japan, and Australia. Published in the prestigious journal Health Affairs, this research challenges long-held assumptions about regulatory efficiency and highlights the pivotal role of pharmaceutical companies' strategic decisions in shaping global drug availability.
The analysis, led by Irene Papanicolas, professor of health services, policy, and practice, along with colleagues Olivier J. Wouters and Tania Sawaya, meticulously examined hundreds of new drugs approved between 2014 and 2018. By tracking submission timelines and review processes up to 2022 across five major regulators—the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and Australia's Therapeutic Goods Administration (TGA)—the researchers uncovered patterns that explain the U.S. advantage.
At its core, the study reveals that the U.S. does not necessarily approve drugs faster due to superior regulatory speed. Instead, drug manufacturers often prioritize submitting applications to the FDA first, particularly for medications that offer limited additional benefits over existing therapies. This business-driven approach, influenced by the U.S. market's size and pricing flexibility, results in American patients encountering new treatments sooner, even if they may not represent major medical breakthroughs.
📊 Unpacking the Brown University Study's Methodology and Data
To understand the study's robust foundation, it's essential to grasp how the researchers gathered and analyzed their data. They started with every novel prescription drug approved by either the FDA or EMA from 2014 through 2018—a cohort of over 120 drugs that underwent rigorous scrutiny. For each, the team traced subsequent filings to the other four agencies, calculating both the time from initial global submission to each regulator (submission delay) and the duration from submission to approval (review time).
Therapeutic value played a central role in their analysis. Drugs were classified as 'high-value' if regulators deemed them to provide substantial improvements over current options, often based on assessments like the EMA's categorization of medicines with significant clinical benefits. Conversely, 'low-value' drugs offered marginal gains. This distinction proved crucial, as it illuminated how commercial incentives shape submission strategies.
Key data points emerged clearly: The FDA was the first to receive submissions—and thus approve—80% of the drugs studied, amounting to 102 out of 127. Median review times across regulators ranged narrowly from about 9 to 14 months, with the FDA only marginally quicker by weeks to a month for high-value innovations. However, submission delays were stark: relative to the first filing worldwide, the EMA saw delays of 0.6 months on average, Health Canada 7.9 months, PMDA 9.6 months, and TGA even longer in some cases. For low-value drugs, these gaps widened dramatically, sometimes spanning months or years.
- FDA median submission delay: 0 months (first in line).
- EMA: Contributes 20.2% of total approval lag via delays.
- PMDA (Japan): Up to 83.8% of lag from submission timing.
These figures underscore that while regulators operate at comparable speeds, the 'race' begins unevenly at the submission gate.Brown School of Public Health summary
⚖️ Submission Timing: The Real Driver of US Priority
One of the most striking revelations from the Brown study is the dominance of submission timing over review efficiency. Pharmaceutical companies, facing high development costs estimated at over $2 billion per drug, strategically sequence their regulatory filings to maximize returns. The U.S., as the world's largest pharmaceutical market with annual sales exceeding $600 billion, offers unparalleled revenue potential due to limited price controls and negotiations tied to therapeutic value.
In contrast, agencies like the EMA, Health Canada, PMDA, and TGA often require evidence of added clinical benefit to justify reimbursement or coverage. This value-based approach can deter early submissions for low-value drugs, as manufacturers anticipate tougher bargaining or outright restrictions abroad. Consequently, firms file with the FDA promptly to capture U.S. market share—where prices can be 2-3 times higher than in Europe—before tackling international hurdles.
For instance, orphan drugs (those for rare diseases affecting fewer than 200,000 Americans) or those qualifying for FDA priority review (for serious conditions with unmet needs) see even earlier U.S. prioritization. Market exclusivity incentives, like seven years for orphans, further accelerate this trend. As co-author Olivier Wouters noted, "Companies generally seem to submit these lower-value products for approval earlier in the United States than in other markets."
This image illustrates the typical lag: a low-value drug might hit U.S. shelves 12-18 months before Japan, driven purely by delayed PMDA submission.
Photo by the blowup on Unsplash
🎯 High-Value vs. Low-Value Drugs: A Tale of Two Priorities
The study draws a sharp line between drug types, revealing equitable global access for true innovations. High-value drugs—those with clear superiority, such as breakthrough cancer therapies or antivirals—were submitted nearly simultaneously across borders. Review times aligned closely, ensuring patients in the EU, Canada, Japan, and Australia faced minimal delays, often mere weeks behind the U.S.
Low-value drugs tell a different story. These 'me-too' medications, tweaking existing formulas with minor efficacy boosts, flooded the U.S. market first. Examples include incremental antidepressants or statins where generics already abound. Here, submission delays abroad accounted for 70-80% of total access gaps, per the analysis. Irene Papanicolas emphasized, "Historically, yes, the U.S. gets more new drugs and gets them faster... but a lot of what is driving this pattern aren’t the drugs that have meaningful therapeutic gain."
This disparity raises questions about value: While faster U.S. access sounds beneficial, it often means earlier exposure to costlier, less innovative options. Other nations' caution protects public budgets, potentially fostering more judicious healthcare spending.
🌍 Global Regulatory Landscape: How Agencies Compare
Understanding the players is key. The FDA, established in 1906, approves drugs via New Drug Applications (NDAs), aiming for 10-month standard and 6-month priority reviews under the Prescription Drug User Fee Act (PDUFA), funded partly by industry fees.
The EMA centralizes EU approvals since 1995, using similar centralized procedures with 210-day targets, emphasizing pharmacovigilance and added benefit for pricing. Health Canada employs a Notice of Compliance pathway, balancing speed with cost-effectiveness reviews via the Common Drug Review. Japan's PMDA, post-2004 reforms, shortened reviews to 12 months but prioritizes sakigake (fast-track) for innovations. Australia's TGA mirrors this, with 255 working days for priority.
Despite variances, median reviews cluster tightly: FDA ~10 months, EMA 11-12, others 12-14. Harmonization efforts like the International Council for Harmonisation (ICH) minimize redundancies, yet national priorities persist.Fraser Institute on Canada lags
💡 Implications for Patients, Policymakers, and the Pharma Industry
For patients, the study offers reassurance: Life-saving drugs arrive promptly worldwide, but 'priority' access in the U.S. skews toward profitable marginal gains. This could inflate costs—U.S. drug spending hit $405 billion in 2023—burdening insurers and individuals without commensurate health wins.
Policymakers might push for aligned submissions, perhaps via incentives for parallel filings or value-based approvals. The Inflation Reduction Act's price negotiations signal shifting U.S. dynamics, potentially slowing low-value rushes. Industry faces calls for transparency in submission strategies.
Academics and researchers exploring health policy can draw lessons for research jobs in pharmacoeconomics. Aspiring professors might analyze these trends in lectures, encouraging students to rate their courses on platforms like those powered by AcademicJobs.com.
Actionable advice: Patients awaiting approvals should monitor FDA calendars and consult specialists. Advocate for reforms via patient groups, and explore clinical trials for expedited access.
Photo by Charles Chen on Unsplash
📈 Broader Context from Complementary Research
The Brown findings align with others. A 2026 Fraser Institute report shows Canadians wait 90 weeks longer than Americans and 65 weeks past Europeans for new medicines, echoing submission issues. RAND's 2024 analysis confirmed U.S. first-launch dominance for 50%+ of drugs, with one-year average lags elsewhere.
Yet balance exists: Post-approval reimbursement lags more in the U.S., per AJMC, delaying insured access. These views paint a nuanced picture, urging harmonized yet value-driven systems.
🔄 Looking Ahead: Pathways to Equitable Access
As global health challenges evolve—from pandemics to rare diseases—equitable, efficient access remains paramount. The Brown study advocates scrutinizing submission incentives over regulator blame. Future policies could mandate parallel filings for high-value drugs or tie U.S. exclusivity to international timelines.
For those in higher education navigating these issues, opportunities abound in higher ed jobs, particularly in health policy and research faculties. Share your insights on professor effectiveness via Rate My Professor, explore career advice, or pursue university jobs at institutions driving such discoveries. AcademicJobs.com connects seekers with roles shaping tomorrow's policies—faculty positions await.
Engage below in comments to discuss how these findings impact your field or community.